​
​

Kineta Stock (NASDAQ:KA)

OwnershipFinancialsChart
Kineta by TradingView

Previous Close

$0.78

52W Range

$0.33 - $5.39

50D Avg

$0.65

200D Avg

$1.41

Market Cap

$9.42M

Avg Vol (3M)

$710.26K

Beta

0.57

Div Yield

-

KA Company Profile

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Feb 11, 2016

Website

KA Performance

KA Financial Summary

Dec 23Dec 22Dec 21
Revenue$5.44M$1.95M$9.09M
Operating Income$-15.72M$-41.53M$-11.09M
Net Income$-14.10M$-63.07M$-11.96M
EBITDA$-15.71M$-59.98M$-12.16M
Basic EPS$-1.28$-12.80$-2.74
Diluted EPS$-1.28$-12.80$-2.74

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CYTCyteir Therapeutics, Inc.
DYAIDyadic International, Inc.
MLYSMineralys Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
ALVRAlloVir, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
DMACDiaMedica Therapeutics Inc.
CADLCandel Therapeutics, Inc.
INKTMiNK Therapeutics, Inc.
TPSTTempest Therapeutics, Inc.
PEPGPepGen Inc.
SILOSilo Pharma, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
PTIXProtagenic Therapeutics, Inc.
MOLNMolecular Partners AG
FBRXForte Biosciences, Inc.
LUMOLumos Pharma, Inc.
KTRAKintara Therapeutics, Inc.